pubmed-article:7788981 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:7788981 | lifeskim:mentions | umls-concept:C0020971 | lld:lifeskim |
pubmed-article:7788981 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
pubmed-article:7788981 | lifeskim:mentions | umls-concept:C1704689 | lld:lifeskim |
pubmed-article:7788981 | lifeskim:mentions | umls-concept:C1513684 | lld:lifeskim |
pubmed-article:7788981 | lifeskim:mentions | umls-concept:C0599779 | lld:lifeskim |
pubmed-article:7788981 | lifeskim:mentions | umls-concept:C0567416 | lld:lifeskim |
pubmed-article:7788981 | lifeskim:mentions | umls-concept:C0034143 | lld:lifeskim |
pubmed-article:7788981 | lifeskim:mentions | umls-concept:C0393534 | lld:lifeskim |
pubmed-article:7788981 | lifeskim:mentions | umls-concept:C0033684 | lld:lifeskim |
pubmed-article:7788981 | lifeskim:mentions | umls-concept:C0024518 | lld:lifeskim |
pubmed-article:7788981 | lifeskim:mentions | umls-concept:C0003241 | lld:lifeskim |
pubmed-article:7788981 | lifeskim:mentions | umls-concept:C0443211 | lld:lifeskim |
pubmed-article:7788981 | lifeskim:mentions | umls-concept:C1254704 | lld:lifeskim |
pubmed-article:7788981 | lifeskim:mentions | umls-concept:C1524003 | lld:lifeskim |
pubmed-article:7788981 | lifeskim:mentions | umls-concept:C1517945 | lld:lifeskim |
pubmed-article:7788981 | pubmed:issue | 1 | lld:pubmed |
pubmed-article:7788981 | pubmed:dateCreated | 1995-7-27 | lld:pubmed |
pubmed-article:7788981 | pubmed:abstractText | Passive transfer of anti-Yo antibody from patients with paraneoplastic cerebellar degeneration (PCD) associated with gynecological or breast carcinoma has not been successful in inducing an animal model. We used active immunization with recombinant Yo protein of four strains of mice bearing different MHC molecules: BALB/c (H-2d), C3H (H-2k), C57BL/6 (H-2b), SJL/J (H-2s). All the strains produced high anti-Yo antibody titer but none developed cerebellar ataxia or showed Purkinje cell loss. Spleen cells from the immunized mice also reacted with recombinant protein. Because C57BL/6(nu/nu) mice produce no anti-Yo antibody, mature helper T cells are required for its production. Results suggest that antibody production in peripheral blood alone is not sufficient for the development of PCD and that MHC class II molecules function in the activation of T cells to help B cells to help B cells produce antibodies. | lld:pubmed |
pubmed-article:7788981 | pubmed:language | eng | lld:pubmed |
pubmed-article:7788981 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7788981 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:7788981 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7788981 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7788981 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7788981 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7788981 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7788981 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7788981 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7788981 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7788981 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:7788981 | pubmed:month | Feb | lld:pubmed |
pubmed-article:7788981 | pubmed:issn | 0303-8467 | lld:pubmed |
pubmed-article:7788981 | pubmed:author | pubmed-author:TanakaKK | lld:pubmed |
pubmed-article:7788981 | pubmed:author | pubmed-author:TanakaMM | lld:pubmed |
pubmed-article:7788981 | pubmed:author | pubmed-author:TsujiSS | lld:pubmed |
pubmed-article:7788981 | pubmed:author | pubmed-author:OnoderaOO | lld:pubmed |
pubmed-article:7788981 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:7788981 | pubmed:volume | 97 | lld:pubmed |
pubmed-article:7788981 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:7788981 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:7788981 | pubmed:pagination | 95-100 | lld:pubmed |
pubmed-article:7788981 | pubmed:dateRevised | 2009-10-14 | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:meshHeading | pubmed-meshheading:7788981-... | lld:pubmed |
pubmed-article:7788981 | pubmed:year | 1995 | lld:pubmed |
pubmed-article:7788981 | pubmed:articleTitle | Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 1. Mouse strains bearing different MHC molecules produce antibodies on immunization with recombinant Yo protein, but do not cause Purkinje cell loss. | lld:pubmed |
pubmed-article:7788981 | pubmed:affiliation | Department of Neurology, Niigata University, Japan. | lld:pubmed |
pubmed-article:7788981 | pubmed:publicationType | Journal Article | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7788981 | lld:pubmed |